Apis Mellifera Apis Mellifera Venom Euphorbia Resi
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Apis Mellifera Apis Mellifera Venom Euphorbia Resi
- Multi-Ingredient Botanical Combination (Homeopathic): Insufficient Data for Repurposing Evaluation
Multi-Ingredient Botanical Combination (Homeopathic): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This Evidence Pack describes a nine-ingredient botanical/homeopathic combination—including Apis mellifera venom, Euphorbia resinifera resin, histamine dihydrochloride, and six other botanicals—with no registered market authorization in Taiwan, no DrugBank mapping, and no TxGNN-generated repurposing predictions. Without a structured drug entity or predicted indication, a repurposing evaluation cannot be conducted at this stage. No clinical trial or literature evidence is therefore available to support any specific new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — no regulatory authorization found |
| Predicted New Indication | None — TxGNN did not generate predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no model output, no studies) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
TxGNN operates on single molecular entities mapped to the DrugBank knowledge graph. This candidate is a nine-component mixture of botanical extracts and homeopathic dilutions:
| Component | Category |
|---|---|
| Apis mellifera / Apis mellifera venom | Animal-derived / bee venom peptides |
| Euphorbia resinifera resin | Botanical (contains resiniferatoxin, a TRPV1 agonist) |
| Euphrasia stricta | Botanical (eyebright, used in ocular complaints) |
| Hedera helix flowering twig | Botanical (ivy; saponins with expectorant activity) |
| Histamine dihydrochloride | Small molecule (homeopathic dilution) |
| Onion (Allium cepa) | Botanical (quercetin source) |
| Pulsatilla vulgaris | Botanical (pasque flower; used in homeopathy) |
| Schoenocaulon officinale seed | Botanical (sabadilla; alkaloids cevadine/veratridine) |
Because none of these components resolved to a DrugBank ID (drugbank_id: null), the TxGNN pipeline could not construct an entity embedding and therefore produced zero predicted indications. This is an expected pipeline behavior, not a data error.
Based on pharmacological knowledge of individual components, the combination pattern is consistent with European homeopathic products formulated for allergic rhinitis, insect-sting reactions, or upper respiratory complaints (e.g., products in the Apis/Euphrasia/Histamine category). However, this interpretation is not derived from model output and carries no evidentiary weight for repurposing decisions.
Safety Considerations
No safety data is currently available for this combination as a mapped drug entity. Please refer to individual monographs and the original manufacturer’s package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The candidate could not be processed by TxGNN because it lacks a resolvable DrugBank identifier, resulting in zero predicted indications and zero supporting evidence. Without a structured drug entity, no repurposing hypothesis exists to evaluate.
To proceed, the following is needed:
- Entity disambiguation: Determine whether the intended active ingredient is a single lead compound (e.g., resiniferatoxin from Euphorbia resinifera, or melittin/phospholipase A₂ from bee venom) and obtain its DrugBank ID.
- Regulatory clarification: Confirm whether this combination is registered in any jurisdiction (EU, US, Japan) under a homeopathic or botanical drug pathway and retrieve the authorised indications.
- MOA documentation: Retrieve the mechanism of action for the primary active component from DrugBank or literature before re-submitting to the TxGNN pipeline.
- Re-submission: Once a single mappable entity is identified, re-run the TxGNN prediction pipeline for a standard repurposing evaluation.
- Safety baseline: Download the manufacturer’s package insert (or the TFDA equivalent if one exists) to complete the S1 safety screening that is currently blocked (Data Gap DG001).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.